The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
CYP46A1, the rate-limiting enzyme for cholesterol degradation, is neuroprotective in Huntington’s disease
Open accessAbstract
Huntington's disease is an autosomal dominant neurodegenerative disease caused by abnormal polyglutamine expansion in huntingtin (Exp-HTT) leading to degeneration of striatal neurons. Altered brain cholesterol homeostasis has been implicated in Huntington's disease, with increased accumulation of cholesterol in striatal neurons yet reduced levels of cholesterol metabolic precursors. To elucidate these two seemingly opposing dysregulations, we investigated the expression of cholesterol 24-hydroxylase (CYP46A1), the neuronal-specific and rate-limiting enzyme for cholesterol conversion to 24S-hydroxycholesterol (24S-OHC). CYP46A1 protein levels were decreased in the putamen, but not cerebral cortex samples, of post-mortem Huntington's disease patients when compared to controls. Cyp46A1 mRNA and CYP46A1 protein levels were also decreased in the striatum of the R6/2 Huntington's disease mouse model and in SThdhQ111 cell lines. In vivo, in a wild-type context, knocking down CYP46A1 expression in the striatum, via an adeno-associated virus-mediated delivery of selective shCYP46A1, reproduced the Huntington's disease phenotype, with spontaneous striatal neuron degeneration and motor deficits, as assessed by rotarod. In vitro, CYP46A1 restoration protected SThdhQ111 and Exp-HTT-expressing striatal neurons in culture from cell death. In the R6/2 Huntington's disease mouse model, adeno-associated virus-mediated delivery of CYP46A1 into the striatum decreased neuronal atrophy, decreased the number, intensity level and size of Exp-HTT aggregates and improved motor deficits, as assessed by rotarod and clasping behavioural tests. Adeno-associated virus-CYP46A1 infection in R6/2 mice also restored levels of cholesterol and lanosterol and increased levels of desmosterol. In vitro, lanosterol and desmosterol were found to protect striatal neurons expressing Exp-HTT from death. We conclude that restoring CYP46A1 activity in the striatum promises a new therapeutic approach in Huntington's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Protein aggregation and neurodegenerative disease
Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454
Dietschy, J. M., & Turley, S. D. (2004) · Journal of Lipid Research · doi:10.1194/jlr.r400004-jlr200 · Cited by 1,095
Brain Cholesterol: Long Secret Life Behind a Barrier
Björkhem, I., & Meaney, S. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000120374.59826.1b · Cited by 1,044
Lund, E. G., Xie, C., Kotti, T., Turley, S. D., Dietschy, J. M., & Russell, D. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303415200 · Cited by 421
Role of cholesterol in synapse formation and function
Pfrieger, F. W. (2003) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/s0005-2736(03)00024-5 · Cited by 325
Harnessing chaperone-mediated autophagy for the selective degradation of mutant huntingtin protein
Bauer, P. O., Goswami, A., Wong, H. K., Okuno, M., Kurosawa, M., Yamada, M., Miyazaki, H., Matsumoto, G., Kino, Y., Nagai, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1608 · Cited by 280 · cited 1×
“Abnormal hind limb clasping is reminiscent of dystonic movements in mouse models of Huntington’s disease (Stack et al., 2005; Bauer et al., 2010; Paul et al., 2014).”
BackgroundDjelti, F., Braudeau, J., Hudry, E., Dhenain, M., Varin, J., Bièche, I., Marquer, C., Chali, F., Ayciriex, S., Auzeil, N., et al. (2015) · Brain · doi:10.1093/brain/awv166 · Cited by 223
Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses
Sipione, S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.17.1953 · Cited by 209
Sondhi, D., Hackett, N. R., Peterson, D. A., Stratton, J., Baad, M., Travis, K. M., Wilson, J. M., & Crystal, R. G. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300049 · Cited by 170
Cited by
Oxysterols: From cholesterol metabolites to key mediators
Mutemberezi, V., Guillemot-Legris, O., & Muccioli, G. G. (2016) · Progress in Lipid Research · doi:10.1016/j.plipres.2016.09.002 · Cited by 335
Adeno-Associated Virus-Based Gene Therapy for CNS Diseases
Hocquemiller, M., Giersch, L., Audrain, M., Parker, S., & Cartier, N. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.087 · Cited by 291
Self-citationLipid and Lipoprotein Metabolism in Microglia
Loving, B. A., & Bruce, K. D. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00393 · Cited by 255
Loera-Valencia, R., Goikolea, J., Parrado-Fernandez, C., Merino-Serrais, P., & Maioli, S. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.003 · Cited by 214
LXR Regulation of Brain Cholesterol: From Development to Disease
Courtney, R., & Landreth, G. E. (2016) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2016.03.018 · Cited by 190
Bile acid signaling in neurodegenerative and neurological disorders
Grant, S. M., & DeMorrow, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21175982 · Cited by 185
Cellular cholesterol homeostasis and Alzheimer’s disease
Chang, T.-Y., Yamauchi, Y., Hasan, M. T., & Chang, C. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075630 · Cited by 155
Varma, V. R., Büşra Lüleci, H., Oommen, A. M., Varma, S., Blackshear, C. T., Griswold, M. E., An, Y., Roberts, J. A., O’Brien, R., Pletnikova, O., et al. (2021) · npj Aging and Mechanisms of Disease · doi:10.1038/s41514-021-00064-9 · Cited by 153
Bile acids: a communication channel in the gut-brain axis
Monteiro-Cardoso, V. F., Corlianò, M., & Singaraja, R. R. (2021) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08625-z · Cited by 145
CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington’s disease
Kacher, R., Lamazière, A., Heck, N., Kappes, V., Mounier, C., Despres, G., Dembitskaya, Y., Perrin, E., Christaller, W., Sasidharan Nair, S., et al. (2019) · Brain · doi:10.1093/brain/awz174 · Cited by 119
Self-citationStatins and the Brain: More than Lipid Lowering Agents?
Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2018) · Current Neuropharmacology · doi:10.2174/1570159x15666170703101816 · Cited by 116
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases
Feringa, F. M., Koppes-den Hertog, S. J., Wang, L. Y., Derks, R. J. E., Kruijff, I., Erlebach, L., Heijneman, J., Miramontes, R., Pömpner, N., Blomberg, N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01365-z · Cited by 56
Shankaran, M., Di Paolo, E., Leoni, V., Caccia, C., Ferrari Bardile, C., Mohammed, H., Di Donato, S., Kwak, S., Marchionini, D., Turner, S., et al. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.11.013 · Cited by 54
Segatto, M., Tonini, C., Pfrieger, F. W., Trezza, V., & Pallottini, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133317 · Cited by 51
“be the main mechanism to remove cholesterol from CNS [19,20], but data obtained by gas Figure 1.”
BackgroundSREBP2 gene therapy targeting striatal astrocytes ameliorates Huntington’s disease phenotypes
Birolini, G., Verlengia, G., Talpo, F., Maniezzi, C., Zentilin, L., Giacca, M., Conforti, P., Cordiglieri, C., Caccia, C., Leoni, V., et al. (2021) · Brain · doi:10.1093/brain/awab186 · Cited by 48
High levels of 27-hydroxycholesterol results in synaptic plasticity alterations in the hippocampus
Loera-Valencia, R., Vazquez-Juarez, E., Muñoz, A., Gerenu, G., Gómez-Galán, M., Lindskog, M., DeFelipe, J., Cedazo-Minguez, A., & Merino-Serrais, P. (2021) · Scientific Reports · doi:10.1038/s41598-021-83008-3 · Cited by 37
Birolini, G., Valenza, M., Di Paolo, E., Vezzoli, E., Talpo, F., Maniezzi, C., Caccia, C., Leoni, V., Taroni, F., Bocchi, V. D., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012519 · Cited by 27
Cholesterol Metabolism in CNS Diseases: The Potential of SREBP2 and LXR as Therapeutic Targets
Wang, N.-Q., Sun, P.-X., Shen, Q.-Q., & Deng, M.-Y. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04672-w · Cited by 19
Modulation of Brain Cholesterol Metabolism through CYP46A1 Overexpression for Rett Syndrome
Audouard, E., Khefif, N., Gillet-Legrand, B., Nobilleau, F., Bouazizi, O., Stanga, S., Despres, G., Alves, S., Lamazière, A., Cartier, N., et al. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060756 · Cited by 7
“A striatal injection of AAV-CYP46A1 in the R6/2 mouse model of Huntington’s disease restored levels of cholesterol and lanosterol as well as increased levels of desmosterol [30].”
BackgroundResultInfluentialSelf-citation
Metadata
- Authors
- Boussicault, L., Alves, S., Lamazière, A., Planques, A., Heck, N., Moumné, L., Despres, G., Bolte, S., Hu, A., Pagès, C., Galvan, L., Piguet, F., Aubourg, P., Cartier, N., Caboche, J., & Betuing, S.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-29
- Volume
- 139
- Issue
- 3
- Pages
- 953-970
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2279325731
- Cited by
- 197
- References
- 13
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.